Last updated: January 10, 2024
Sponsor: Xijing Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Epidermolysis Bullosa
Pemphigus Vulgaris (Pv)
Treatment
This is a retrospective analysis of health data from inpatient record, no intervention was designed
Clinical Study ID
NCT06213909
XijingH-PF-KY20232420-C-1
Ages < 100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- (1) Patients with Bullous Pemphigoid who were first hospitalized in the Department ofDermatology of Xijing Hospital
- (2) Age 0-100 years old, gender is not limited.
- (3) Diagnosis is confirmed by clinical, histopathologic, immunopathologic and/oranti-BP180 antibody tests.
- (4) Complete skin histopathology information
Exclusion
Exclusion Criteria:
- (1) Patients with Bullous Pemphigoid who were not first diagnosed in our hospital.
- (2) Those who have received systemic glucocorticoid, immunosuppressant, biologic, orother drug therapy within the past month.
Study Design
Total Participants: 318
Treatment Group(s): 1
Primary Treatment: This is a retrospective analysis of health data from inpatient record, no intervention was designed
Phase:
Study Start date:
January 11, 2024
Estimated Completion Date:
June 30, 2024
Connect with a study center
Xijing Hospital
Xi'an, Shaanxi 710032
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.